GW0742 - 30ml/750mg
GW 0742 is a potent and highly selective PPARδ agonist. Research has shown that GW-0742 has the following benefits:
– Significantly increases resistance to physical exertion
– Drastically improves aerobic performance
– Extremely effective for fat loss
– Improves lipid profiles
– Regulates blood sugar (antidiabetic effect)
– Anti inflammatory properties
GW-0742: [4-[[[2-[3-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy]acetic acid
Molecular Formula: C21H17F4NO3S2
Molecular Weight: 471.49 g/mol
CAS number: 317318-84-6
Purity: Greater than 99%
Other details: No DMSO or other harmful solvents
Storage: This product must be stored at 4°C. Not suitable for freezing.
Shake well before use.
GW-0742 (Super Cardarine) was born from the evolution of the well-known Cardarine GW-501516, with respect to which GW-0742 differs in a synthesis and biological activity up to 200 times greater.
GW-0742 is a highly selective modulator of β / δ PPARs. Activation of this particular variety of receptors promotes the expression of genes that modulate cellular metabolism.
Its ability is to reduce fat quickly and extremely while keeping muscle mass intact.
GW-0742 promotes the loss of fat tissue by increasing glucose absorption and improving energy metabolism. Transforms fat into energy and increases resistance to physical effort.
Other studies show that it is an effective neuroprotector by relieving changes in astrocytes it fights neurodegenerative processes.
In particular, GW 0742 enhances the loss of adipose tissue by increasing glucose uptake in skeletal muscle tissue, which changes the body's metabolism. It enhances the oxidation of fatty acids, increasing the mitochondrial density in the cells. In addition, the use of fats as a source of energy contributes to obtaining the desired, low body fat. The compound perfectly uses the stores of fat from cells, as well as fats from the daily diet, using it as a fuel for muscles. It turns fat into energy without lowering blood sugar levels.
It was originally developed to treat obesity and other metabolic diseases, but it has gained immense popularity in bodybuilding due to its ability to burn fat quickly.
As has already been said above,, GW 0742 is also used in the process of building muscle tissue. The mechanism of action is based on the stimulation of the expression of anti-inflammatory cytokines IL-10 and TGF-β mRNA. Studies show that the agent greatly influences the process of increasing the rate of myogenesis, and in the case of muscle damage, complete regeneration takes place twice as fast.
GW-0742 clearly increases the number of mitochondria in the muscle tissue, which translates into an increase in muscle efficiency. The high concentration of mitochondria allows you to increase the efficiency of metabolic processes, which allows you to generate more ATP. Finally, it increases the strength of muscle contraction and extends the maximum time of aerobic work.
Moreover, GW-0742 intensifies the chondrogenesis process, contributing to the protection of joints against degeneration. The agent has a beneficial effect on the condition of cartilage and joints, promoting the synthesis of type II collagen and glycosaminoglycan, components of cartilage in humans. In addition, GW-0742 influences the increased secretion of transforming growth factor beta (TGF-β), which affects the optimal condition of the joints. The factor TGF-β reduces the level of ossification, reduces inflammation and increases the stability of cartilages.
kai-Chun Cheng et al., "GW0742 activates peroxisome proliferator-activated receptor δ to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells" [PubMed]
M. Galuppo et al., "GW0742, a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice" [PubMed]
Ho-Shan Niu et al., "Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals" [PubMed]
P. Nanhikonda et al., "Peroxisome proliferation-activated receptor δ agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor" [PubMed]
K. Chehaibi et al., "Effect of PPAR-β/δ agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury" [PubMed]
F. Briand et al., "Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol" [PubMed]
S.F. Ahmad et al., "The PPARδ agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model" [PubMed]
E. Benedetti et al., "The PPARβ/δ Agonist GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons: Role of PPARβ/δ in Neuronal Maturation" [PubMed]
This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.
All product information provided on this website is for informational and educational purposes only.